Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial.
Daemen, Joost; Kuck, Karl Heinz; Macaya, Carloset al.
2008 • In Journal of the American College of Cardiology, 52 (24), p. 1957-67
[en] OBJECTIVES: The purpose of this study was to assess the 3-year outcome of coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SES) in patients who had multivessel coronary artery disease with and without diabetes mellitus. BACKGROUND: The optimal method of revascularization in diabetic patients remains in dispute. METHODS: The ARTS-II (Arterial Revascularization Therapies Study-Part II) trial is a single-arm study (n = 607) that included 159 diabetic patients treated with SES whose 3-year clinical outcome was compared with that of the historical diabetic and nondiabetic arms of the randomized ARTS-I trial (n = 1,205, including 96 diabetic patients in the CABG arm and 112 in the PCI arm). RESULTS: At 3 years, among nondiabetic patients, the incidence of the primary composite of death, CVA, myocardial infarction (MI), and repeat revascularization (major adverse cardiac and cerebrovascular events [MACCE]), was significantly lower in ARTS-II than in ARTS-I PCI (adjusted odds ratio [OR]: 0.41; 95% confidence interval [CI]: 0.26 to 0.64) and similar to ARTS-I CABG. The ARTS-II patients were at significantly lower risk for death, CVA, and MI as compared with both the ARTS-I PCI (adjusted OR: 0.55; 95% CI: 0.34 to 0.91) and ARTS-I CABG patients (adjusted OR: 0.56; 95% CI: 0.35 to 0.92). Among diabetic patients, the incidence of MACCE in ARTS-II was similar to that of both PCI and CABG in ARTS-I. Conversely, the incidence of death, CVA, and MI was significantly lower in ARTS-II than in ARTS-I PCI (adjusted OR: 0.67; 95% CI: 0.27 to 1.65) and was similar to that of ARTS-I CABG. CONCLUSIONS: At 3 years, PCI using SES for patients with multivessel coronary artery disease seems to be safer and more efficacious than PCI using bare-metal stents, irrespective of the diabetic status of the patient. Hence, PCI using SES appears to be a valuable alternative to CABG for both diabetic and nondiabetic patients.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Daemen, Joost
Kuck, Karl Heinz
Macaya, Carlos
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial.
King III S.B., Kosinski A.S., Guyton R.A., Lembo N.J., and Weintraub W.S. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). J Am Coll Cardiol 35 (2000) 1116-1121
Mercado N., Wijns W., Serruys P.W., et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg 130 (2005) 512-519
Serruys P.W., Ong A.T., van Herwerden L.A., et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46 (2005) 575-581
Rodriguez A.E., Baldi J., Fernandez Pereira C., et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol 46 (2005) 582-588
Hueb W., Lopes N.H., Gersh B.J., et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115 (2007) 1082-1089
Javaid A., Steinberg D.H., Buch A.N., et al. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. Circulation 116 (2007) I200-I206
Serruys P.W., Ong A.T., Morice M.C., et al. Arterial Revascularisation Therapies Study Part II: sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. Euro Interv 1 (2005) 147-156
Rodriguez A.E., Maree A.O., Grinfeld L., et al. Revascularization strategies of coronary multivessel disease in the drug-eluting stent era: one year follow-up results of the ERACI-III trial. Euro Interv 2 (2006) 53-60
Kip K.E., Faxon D.P., Detre K.M., Yeh W., Kelsey S.F., and Currier J.W. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute percutaneous transluminal coronary angioplasty registry. Circulation 94 (1996) 1818-1825
Thourani V.H., Weintraub W.S., Stein B., et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 67 (1999) 1045-1052
West N.E., Ruygrok P.N., Disco C.M., et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 109 (2004) 867-873
Niles N.W., McGrath P.D., Malenka D., et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 37 (2001) 1008-1015
de la Torre-Hernandez J.M., Rumoroso J.R., Perez de Prado A., et al. Differential predictors for subacute, late and very late drug-eluting stent thrombosis: results from the multicenter ESTROFA study. Paper presented at: Annual Scientific Sessions of the American College of Cardiology; March 24-27 (2007) New Orleans, LA
Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
Daemen J., Garcia-Garcia H.M., Kukreja N., et al. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 28 (2007) 26-32
Serruys P.W., Lemos P.A., and van Hout B.A. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart 90 (2004) 995-998
Tsuchida K., Colombo A., Lefevre T., et al. The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II). Eur Heart J 28 (2007) 433-442
Valgimigli M., Dawkins K., Macaya C., et al. Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial. J Am Coll Cardiol 49 (2007) 431-441
van den Brand M.J., Rensing B.J., Morel M.A., et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 39 (2002) 559-564
Serruys P.W., Unger F., van Hout B.A., et al. The ARTS study (Arterial Revascularization Therapies Study). Semin Interv Cardiol 4 (1999) 209-219
Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344 (2001) 1117-1124
Abizaid A., Costa M.A., Centemero M., et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104 (2001) 533-538
Serruys P., Daemen J., Morice M.C., et al. Three-year follow-up of the ARTS-II: sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. Euro Interv (2008) 450-458
Alderman E.L. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 96 (1997) 1761-1769
Kurbaan A.S., Bowker T.J., Ilsley C.D., Sigwart U., and Rickards A.F. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol 87 (2001) 947-950
Jimenez-Quevedo P., Sabate M., Angiolillo D.J., et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 28 (2007) 1946-1952
Tu J.V., Bowen J., Chiu M., et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 357 (2007) 1393-1402
James S. Long term mortality after drug-eluting stents in Sweden-one additional year of follow-up. Paper presented at: European Society of Cardiology; September 1-5 (2007) Vienna, Austria
Daemen J., Van Domburg R., Boersma E., de Jaegere P., and Serruys P. A long-term survival analysis of 3 sequential cohorts of consecutive all comers (n = 6129) treated with either bare-metal, sirolimus- or paclitaxel-eluting stents: an epidemiological analysis requested by the directing board of a Dutch tertiary medical center. Paper presented at: European Society of Cardiology; September 1-5 (2007) Vienna, Austria
Mauri L., Silverstein T., Lovett A., Resnic F.S., and Normand S. Long term clinical outcomes following drug-eluting and bare metal stenting in Massachusetts. Paper presented at: American Heart Association Scientific Sessions; November 4-7 (2007) Orlando, FL
Jensen L.O., Maeng M., Kaltoft A., et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 50 (2007) 463-470
Lincoff A.M. Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation 107 (2003) 1556-1559
Aronson D., Bloomgarden Z., and Rayfield E.J. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 27 (1996) 528-535
Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54 (2005) 2430-2435
Angiolillo D.J., Bernardo E., Ramirez C., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48 (2006) 298-304
Schwartz S.M., and Bornfeldt K.E. How does diabetes accelerate atherosclerotic plaque rupture and arterial occlusion?. Front Biosci 8 Suppl (2003) 1371-1383
Stankovic G., Cosgrave J., Chieffo A., et al. Impact of sirolimus-eluting and paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol 98 (2006) 362-366
Ong A.T., Serruys P., Mohr F.W., et al. The Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) study: design, rationale and run-in phase. Am Heart J 151 (2006) 1194-1204
Kapur A., Malik I.S., Bagger J.P., et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J 149 (2005) 13-19
